Seoochre

The pharmaceutical industry is undergoing a profound shift with the adoption of digital transformation, offering opportunities for operational excellence. Key aspects include data-driven decision-making, supply chain optimization, accelerated R&D through AI, enhanced regulatory compliance, and a patient-centric approach. Despite benefits, challenges like data security, integration complexities, and workforce upskilling must be addressed for the industry to fully realize the potential of digital transformation. In conclusion, embracing advanced technologies is crucial for operational excellenc

In the realm of cancer therapeutics, pharmacogenomics has emerged as a critical linchpin in shaping treatment decisions. The relentless adaptability of cancer cells, often culminating in resistance to chemotherapy and targeted therapies, underscores the pressing need for a more targeted approach. Pharmacogenomics, through the illumination of genetic mutations underpinning drug resistance, offers a powerful compass for oncologists. This genetic insight not only permits the tailoring of individualized treatment plans but also facilitates the precise selection of drugs most likely to exert a the

Automation and Robotics: Automation and robotics have emerged as transformative forces in reshaping pharmaceutical manufacturing in North America. The strategic integration of automated systems has yielded significant improvements, streamlining production processes and yielding notable increases in efficiency while concurrently minimizing errors. Robotics, a cornerstone of this technological revolution, assumes critical roles across various tasks, encompassing routine activities such as packaging and sorting to more intricate procedures like drug synthesis.

Incorporating robotics into phar

Education and training form the foundation for successful patient recruitment in healthcare. It is imperative to ensure that clinical staff members are well-informed and equipped with the necessary knowledge about ongoing and upcoming clinical trials. This involves providing comprehensive training that delves into the intricacies of each study, covering aspects such as inclusion and exclusion criteria, study objectives, and the potential benefits to patients.

Equipping clinical staff with a comprehensive grasp of inclusion and exclusion criteria enables precise identification of eligible p

Furthermore, the influence of GDPR extends far beyond the borders of the EU. Its robust framework has set a precedent globally, inspiring and influencing data protection regulations in various countries. Many jurisdictions have taken cues from the GDPR's principles, adapting and enhancing their legal frameworks to align with the evolving expectations for safeguarding individuals' privacy in an increasingly digital world. As businesses strive to navigate this intricate landscape, the GDPR catalyzes a global paradigm shift in how personal data is handled, emphasizing the importance of ethical a

The pharmaceutical sector is experiencing a noteworthy transition towards patient-centered methodologies, integrating patient insights into research, embracing personalized medicine, incorporating digital health technologies, encouraging patient involvement in decision-making, highlighting post-market surveillance, and evolving regulatory frameworks. These changes signify the potential for a more personalized, inclusive, and effective healthcare system in the future. The pharmaceutical industry is undergoing a paradigm shift towards patient-centered approaches, recognizing the importance of c

Pharmaceutical manufacturing faces significant environmental challenges, primarily centered around high energy consumption, substantial waste generation, and intensive water usage. The industry's carbon footprint is a pressing concern, contributing to climate change. The energy-intensive processes involved in drug production, coupled with the generation of substantial waste streams, underscore the need for sustainable practices. Additionally, the water-intensive nature of pharmaceutical manufacturing amplifies concerns about resource depletion and environmental impact. Addressing these challe

The pharmaceutical sector encounters intricate data security challenges in its IT setup, encompassing data sensitivity, regulatory compliance, cybersecurity threats, supply chain risks, and insider threats. Addressing these issues necessitates implementing strong access controls, adhering to compliance standards, employing cybersecurity protocols, scrutinizing the supply chain, and providing comprehensive employee training. To ensure operational integrity and safeguard sensitive information, a continual commitment to adaptation, collaboration, and investment in advanced technologies is indisp

Artificial Intelligence (AI) and machine learning-based technologies have the potential to transform healthcare because they offer new and important insights derived from the vast amount of data generated during the delivery of healthcare every day. The capacity of AI to learn from real-world feedback and improve its performance makes this technology uniquely suited as Software as a Medical Device (SaMD) and is responsible for it being a rapidly expanding area of research and development. Clinical pharmacy practice may undergo major change due to the implementation of this technology.

Controlling the industrial crystallisation process poses a significant obstacle in the production of drugs and numerous other products. Digitisation of the crystallisation process now allows for radical change by increasing process automation to control overall crystallisation. The main pillars of Pharma 4.0 are process automation, improved control strategies, data visualisation, cloud edge storage, chemometrics, and mathematical modelling technologies. SmartCrys is a revolutionary integrated process control system that harnesses the mainstays of Pharma 4.0 with the combination of PAT tools i

By applying artificial intelligence (AI) and data science approaches, organisations can turn the overabundance of data from being a challenge to solve, into an opportunity. A well-designed, automated, AI-powered PV system can not only eliminate tedious and repetitive tasks but also reduce human errors and analyse massive volumes of data efficiently. This can even empower teams with predictive signal detection capabilities with insights derived from integrating disparate big data sources. Ultimately, this can enable specialists to make more informed observations and recommendations on product

Clinical research technology platforms have also emerged, providing participant-facing apps and websites where you can build in or interface with some or all the previously mentioned solutions, as well as expanding to other research-related activities such as virtual training, electronic informed consent form (eICF), participant recruitment, engagement, visit reminders and concierges, etc. Implementing these platforms, the individual participant is given an even more active role in their own research journey, as they are responsible to enter their own subjective data directly into the designa

The pharmaceutical industry is expected to be worth $1.5 trillion by 2023, and the field of pharmacovigilance plays a crucial role in ensuring the safety of drugs. Artificial Intelligence (AI) and Machine Learning (ML) models are being applied to improve the pharmacovigilance process, including case intake using Optical Character Recognition (OCR) and Natural Language Processing (NLP), natural language generation (NLG) for narrative writing, robotic process automation (RPA) for dynamic case workflow, AI-based signal detection, and AI-based adverse event prediction. These advancements have the

The global pharmaceutical industry is currently facing many, wide ranging, challenges, including an aging population, increased life expectancy, a rise in chronic conditions, reduced funding for treatments, reduced numbers of clinical staff, the ever increasing cost of drug development and raw materials, and supply chain issues. Consequently, the pharmaceutical industry is increasingly looking at how a wealth of data, including compound libraries, trial data, and patient data, can be used and reused by artificial intelligence (“AI”) to alleviate these challenges and improve patient care.

However, these efforts are haunted by a shortage of resources, restrictions on importing API, social distancing at facilities, disturbed supply chains, and tremendous pressure to quickly manufacture and distribute products. Despite these arduous circumstances, it remains critical for pharma companies to maintain quality and compliance and follow regulatory guidelines. Doing so requires pertinent measures to ensure adherence to Current Good Manufacturing Practice (CGMP) guidelines, and data integrity to meet the requirements of regulators including the U.S. Food and Drug Administration (FDA),

In August 2021, ransomware operators targeted the health department of the Italian region of Lazio and disabled its COVID-19 vaccination booking system, disrupting the scheduling of new vaccination appointments for days.

Since it contains the city of Rome and is one of Italy’s most densely populated areas, Lazio was an attractive target because of the strong desire among its people to get vaccinated and gain its Green Pass vaccine passport. Hackers likely believed that this would pressure the authorities to pay up the ransom to unlock the systems they had disabled through a cyberattack.

While the life sciences sector has incrementally adopted digital technologies over the years, the rate of digital transformation over the next five years looks to be unprecedented. Collaborations and acquisitions in the pursuit of digital transformation have accelerated significantly. In 2018, US$9.5 billion was invested in the digital health sector over 698 deals. From the FDA approval of Otsuka’s sensor embedded drug Abilify Mycite and the approval of Pear Therapeutics’ app for the treatment of opioid abuse, through to Takeda’s partnership with Emulate Inc for the use of organs on chips for

Big pharma is gradually and progressively riding the social media bandwagon with a host of tactics towards listening, analytics, engagement, brand promotions, and much more. This has meant successful handling of the regulatory hurdles — what to share, what not to share, how much to share and most importantly the safety events that need to be reported. But even as all of this is afoot, companies are generally observed to be reticent in embracing social media wholeheartedly. While companies in other industries may only fret over a social media faux pas because it can potentially lead to public

To bring this into reality, pharmaceutical PV organisations need to move into a “digitalised future” where technology plays a key role in PV processes. This includes automating and streamlining the information streams to reduce complexity, from case processing to reporting. Once automated, companies need to begin to look to artificial intelligence to add further value from their data.

By applying artificial intelligence (AI) and data science approaches, organisations can turn the overabundance of data from being a challenge to solve, into an opportunity. A well-designed, automated, AI-powe

Nanomaterials have been one of the most exciting scientific and technical innovations of the past few decades. Due to their very high surface to volume ratios, they exhibit properties that can differ dramatically from those for the same material in bulk. This, and their ability to be designed and synthesized with multiple surface functionalities, has seen them used for a myriad of bespoke applications in industry and medicine.

Their medical applications span delivery systems for drugs, proteins and DNA/RNA to diagnostics, targeted cancer treatments, to theranostics. They have been used ver